Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13054-015-1109-0 http://scihub22266oqcxt.onion/10.1186/s13054-015-1109-0 C4641392!4641392!26556106     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Crit+Care 2015 ; 19 (ä): ä Nephropedia Template TP {{tp|p=26556106|t=2015. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial |pdf=|usr=}}{{26556106}} gab.com Text Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial JO: Crit Care http://www.kidney.de/pget.php?&tw=1&pmid=26556106 #FOAvip Introduction: The aim of this study was to collect data in France in patients with heparin-induced thrombocytopenia who required parenteral anticoagulation and for whom other non-heparin anticoagulant therapies were contraindicated including patients with renal failure, cross-reactivity to danaparoid or at high hemorrhagic risk. Methods: A total of 20 patients, of mean age 72?±?10 years, were enrolled in this open-label, multicenter clinical study. Exploratory statistical data analysis was performed with descriptive interpretation of intra-individual comparisons using simple univariate statistics. Results: The diagnosis of HIT was confirmed in 16 subjects by an independent scientific committee. Fourteen patients (70 %) were in an intensive care unit during the course of the study. Patients were treated with argatroban for a mean duration of 8.5?±?6.1 days. The mean starting dose of argatroban was 0.77?±?0.45 ?g/kg/min. Platelet recovery was rapid.aPTT and anti-IIa activity assays were used to monitor the dose of argatroban. The mean baseline aPTT value was 45.0?±?9.8 sec and increased to 78.2?±?35.8 sec two hours after initiating argatroban. At this time mean argatroban concentration was 0.34?±?0.16 and 0.61?±?0.28 ?g/ml using ECT and TT measurements, respectively. New and/or extended thromboses were reported in 25 % of patients and major bleedings were documented in 15 %. Six patients died due to their underlying medical condition. Conclusion: Considering its hepatic elimination and its short half-life, argatroban can be considered as a safe therapeutic option in HIT patients at high hemorrhagic risk and with renal failure, particularly in an ICU setting. Twit Text FOAVip Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial ????Crit Care http://www.kidney.de/pget.php?&tw=1&pmid=26556106 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26556106 #FOAvip English Wikipedia <ref>{{Cite pmid|26556106}}</ref> Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial #MMPMID26556106 Tardy-Poncet B; Nguyen P; Thiranos JC; Morange PE; Biron-Andréani C; Gruel Y; Morel J; Wynckel A; Grunebaum L; Villacorta-Torres J; Grosjean S; de Maistre E Crit Care 2015[]; 19 (ä): ä PMID26556106show ga Introduction: The aim of this study was to collect data in France in patients with heparin-induced thrombocytopenia who required parenteral anticoagulation and for whom other non-heparin anticoagulant therapies were contraindicated including patients with renal failure, cross-reactivity to danaparoid or at high hemorrhagic risk. Methods: A total of 20 patients, of mean age 72?±?10 years, were enrolled in this open-label, multicenter clinical study. Exploratory statistical data analysis was performed with descriptive interpretation of intra-individual comparisons using simple univariate statistics. Results: The diagnosis of HIT was confirmed in 16 subjects by an independent scientific committee. Fourteen patients (70 %) were in an intensive care unit during the course of the study. Patients were treated with argatroban for a mean duration of 8.5?±?6.1 days. The mean starting dose of argatroban was 0.77?±?0.45 ?g/kg/min. Platelet recovery was rapid.aPTT and anti-IIa activity assays were used to monitor the dose of argatroban. The mean baseline aPTT value was 45.0?±?9.8 sec and increased to 78.2?±?35.8 sec two hours after initiating argatroban. At this time mean argatroban concentration was 0.34?±?0.16 and 0.61?±?0.28 ?g/ml using ECT and TT measurements, respectively. New and/or extended thromboses were reported in 25 % of patients and major bleedings were documented in 15 %. Six patients died due to their underlying medical condition. Conclusion: Considering its hepatic elimination and its short half-life, argatroban can be considered as a safe therapeutic option in HIT patients at high hemorrhagic risk and with renal failure, particularly in an ICU setting. äArgatroban in the management of heparin-induced thrombocytopenia: a mu(epmc).pdf DeepDyve Pubget Overpricing